Abstract
Weight gain, diabetes, and changes in serum lipid profiles have been reported during treatment with typical and atypical antipsychotics. An association between diabetes and psychotic disorders was described long before the introduction of pharmacological agents for the treatment of schizophrenia. Several theories have been proposed to explain the baseline weight increase and metabolic disturbances in schizophrenia. Some studies suggest that increased food intake may improve psychotic symptoms in patients with schizophrenia but there have been conflicting results. Available clinical and basic research findings are discussed to evaluate the hypothesis that increased food intake may decrease sensitivity to dopamine signaling in the striatum. More research is needed to evaluate this potential link. However, basic animal research and evolutionary approaches can provide insights into metabolic disturbances associated with schizophrenia.
Keywords: Psychosis, Food Intake, Hypothesis, Weight gain, diabetes, pharmacological agents, schizophrenia, dopamine signaling
Current Molecular Pharmacology
Title: Can Increased Food Intake Improve Psychosis? A Brief Review and Hypothesis
Volume: 1
Author(s): T. Treuer, J. Karagianis and V. P. Hoffmann
Affiliation:
Keywords: Psychosis, Food Intake, Hypothesis, Weight gain, diabetes, pharmacological agents, schizophrenia, dopamine signaling
Abstract: Weight gain, diabetes, and changes in serum lipid profiles have been reported during treatment with typical and atypical antipsychotics. An association between diabetes and psychotic disorders was described long before the introduction of pharmacological agents for the treatment of schizophrenia. Several theories have been proposed to explain the baseline weight increase and metabolic disturbances in schizophrenia. Some studies suggest that increased food intake may improve psychotic symptoms in patients with schizophrenia but there have been conflicting results. Available clinical and basic research findings are discussed to evaluate the hypothesis that increased food intake may decrease sensitivity to dopamine signaling in the striatum. More research is needed to evaluate this potential link. However, basic animal research and evolutionary approaches can provide insights into metabolic disturbances associated with schizophrenia.
Export Options
About this article
Cite this article as:
Treuer T., Karagianis J. and Hoffmann P. V., Can Increased Food Intake Improve Psychosis? A Brief Review and Hypothesis, Current Molecular Pharmacology 2008; 1 (3) . https://dx.doi.org/10.2174/1874467210801030270
DOI https://dx.doi.org/10.2174/1874467210801030270 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Evaluating Drug Safety in Children and Adolescents with Bipolar Disorder
Current Drug Safety Therapeutic Strategies in Parkinsons Disease
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Clozapine Safety, 35 Years Later
Current Drug Safety Advances in Clinical Study of Curcumin
Current Pharmaceutical Design [General Articles] Cannabinoids: Mechanisms and Therapeutic Applications in the CNS
Current Medicinal Chemistry Conference Report (42nd Annual Meeting of the Italian Society of Neurology, 22-25 October 2011, Turin, Italy)
CNS & Neurological Disorders - Drug Targets Mesenchymal Stem Cells as a Source of Dopaminergic Neurons: A Potential Cell Based Therapy for Parkinson's Disease
Current Stem Cell Research & Therapy Schizophrenia: From Dopamine to Glutamate and Back
Current Medicinal Chemistry Attention Deficit and Hyperactivity Disorder: Controversies of Diagnosis and Safety of Pharmacological and Nonpharmacological Treatment
Current Drug Safety Mitochondrial Dysfunction in Huntington’s Disease: Pathogenesis and Therapeutic Opportunities
Current Drug Targets Patterns of Self-Medication with Medicinal Plants and Related Adverse Events - A South American Survey
Current Drug Safety Selected Natural and Synthetic Agents Effective against Parkinson’s Disease with Diverse Mechanisms
Current Topics in Medicinal Chemistry Recent updates on the dynamic association between oxidative stress and neurodegenerative disorders
CNS & Neurological Disorders - Drug Targets Novel Adverse Events of Iloperidone: A Disproportionality Analysis in US Food and Drug Administration Adverse Event Reporting System (FAERS) Database
Current Drug Safety Tau as a Therapeutic Target for Alzheimers Disease
Current Alzheimer Research Imaging Endogenous Neurotransmitters In Vivo with Positron Emission Tomography Displacement Studies
Current Psychopharmacology Tardive Dyskinesia with Atypical Antipsychotic Drugs
Current Drug Therapy Prader-Willi Syndrome: Clinical Genetics and Diagnostic Aspects with Treatment Approaches
Current Pediatric Reviews Modulation Effects of Piracetam and Ginkgo biloba on the Cognitive and Working Memory Functions: Psychometric Study
Current Psychopharmacology Behavioural Sensitisation During Dopamine Replacement Therapy in Parkinsons Disease is Reminiscent of the Addicted Brain
Current Topics in Medicinal Chemistry